Clinical trials: Depressed
Schizophrenia, Bipolar Disorder
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
The purpose of this study is to find out how well new treatment plans are followed by outpatients with major mental illnesses (schizophrenia, bipolar disorder, depression, personality disorder) and to determine the relationship…
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Personality Disorder
- Trial name
- NCT00264069
- Testing
- antipsychotic, antidepressants
- Volunteers
- 2,622 people
- Sponsor
- Janssen-Cilag, S.A.
Depression
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram + Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score measured by the Hamilton Scale (HAM-D).
- Trial name
- LABCATTCJUSS (NCT02532660)
- Testing
- Escitalopram 10mg, LABCAT TCJUSS
- Where
- Brazil
- Volunteers
- 111 people
- Sponsor
- Laboratório Catarinense SA
Depressive Disorder, Treatment-Resistant
Epidemiology of Treatment Resistant Depression in Taiwan
The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.
- Trial name
- NCT02691520
- Volunteers
- 8,356 people
- Sponsor
- Janssen Research & Development, LLC
Depression
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of Psychiatric Electroencephalogram Registry (PEER) Interactive to inform medication prescription in subjects with a…
- Trial name
- SMART-MD (NCT02988076)
- Testing
- PEER Interactive Report
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- MYnd Analytics
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Respiratory Depression
ENA-001 for Opioid Induced Respiratory Depression
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
- Trial name
- NCT06967259
- Testing
- ENA-001
- Where
- 2 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Enalare Therapeutics Inc.
Major Depressive Disorder
An EEG Study of Intravenous Ketamine for Major Depression Disorder
There are many common pharmacological treatments for major depression disorder (MDD), however the efficacy of these drugs often fails in severe cases.
- Trial name
- NCT05506462
- Testing
- Ketamine Hydrochloride
- Volunteers
- 35 people
- Sponsor
- Ehave Inc.
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Bipolar Disorder, Depression, Bipolar
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- NCT00060489
- Testing
- SEROQUEL (quetiapine fumarate) Tablets
- Where
- 27 sites in United States
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Anxiety Disorders, Depression
TAO Outpatient Trial for Anxiety and Depression
Access to effective treatment resources is a ubiquitous problem in behavioral health. There is a need for effective interventions that are more easily accessed at a lower cost.
- Trial name
- NCT03390218
- Testing
- Therapy Assistance Online, Treatment as usual
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- TAO Connect, Inc.
Mental Health Issue, Depression
Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders
US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants complete a survey upon enrollment and are randomized into one of two study arms.
- Conditions
- Mental Health Issue, Depression, Anxiety
- Trial name
- NCT06502717
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Bipolar Depression, Suicidal Ideation and Behavior
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression…
- Trial name
- NCT03395392
- Testing
- NRX-101, Lurasidone HCl
- Where
- 14 sites in United States
- Volunteers
- 74 people
- Sponsor
- NeuroRx, Inc.
Depression
Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects
This is a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation in depressed human subjects study.
- Trial name
- NCT01520649
- Testing
- NSI-189 Phosphate, microcrystalline cellulose capsules
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neuralstem Inc.
Psychological Stress, Sleep Disturbance
Sleep More, Stress Less: 90-Day Trial of Neuralli Mood
This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in…
- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms
- Trial name
- NM90 (NCT07717385)
- Testing
- Neuralli Mood
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Depression
The Taste-Mood Diagnostic Study
The study looks at whether a taste test device can be used as a diagnostic aid for depression. Taste tests will be carried out before and after first use of an antidepressant (prescribed by the patient's GP) and then again six to…
- Trial name
- NCT03645447
- Testing
- Taste test
- Where
- 4 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- Ranvier Health Ltd